Product sheet

HEK293-TACD2 | 305424

Description	/ HEK293-TACD2 HEK293 TACD2 TACD2
Organism	
Tissue	
Disease	/; (HEK293)
Applications	ADC TROP2 (TACD2/TACSTD2) (sacituzumab govitecan analogs);

Age	
Gender	
Morphology	
Cell type	
Growth properties	,

Citation	HEK293-TACD2 (Cytion 305424)
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_6G29

HEK293-TACD2 | 305424

GMO Status	GMO-S1: HEK293 TACD2

Receptors expressed

Receptors expressed	TACD2 (TROP2 GA733-1)

Culture Medium

Culture Medium	RPMI 1640, w: 2.0 mM , w: 2.0 / NaHCO3 (Cytion 820700a)
Supplements	FBS 10%, 1 , HEPES 10 , NEAA 1%
Dissociation Reagent	-
Doubling time	24-36
Subculturing	: PBS
Split ratio	1 5
Seeding density	2 4 x 10 /
Fluid renewal	2 3
Post-Thaw Recovery	1:2 1:3 T25
Freeze medium	(FBS) + 10% DMSO

HEK293-TACD2 | 305424

Thawing and Culturing Cells	1. 2. cryovial -150 3. 37°C 4. 70% 5. 15 6. 300 x g 3 7. 10 8.
Incubation Atmosphere	37°C, 5% $_{CO2}$,
Flask Coating	
Freezing Procedure	
Shipping Conditions	
Storage Conditions	−150 −196 °C

Sterility	PCR